Evaluation of PK and Safety of D-0120 and Allopurinol

Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Spaulding Clinical

West Bend, Wisconsin, 53095, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy subjects between the ages of 18-55
Required evaluation by Investigator for screening and enrollment
Agreement and compliance with the study and follow-up procedures

Exclusion criteria

Significant medical history or current comorbidly determined by the Investigator.
Pregnant or nursing women

Treatment and study plan

D-0120 in combination with Allopurinol

Drug

noted above

Primary outcomes

Type, incidence, severity and attribution of AEs.

Time frame: 14 days

Evaluation of safety between D-0120 and Allopurinol
Plasma concentration of D-0120 and Allopurinol

Time frame: 14 days

Evaluation of exposure between D-0120 and Allopurinol

Sponsors and collaborators

Lead sponsor

InventisBio Co., Ltd

Industry

Registry information

Official study title

A Phase I, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic Interactions Between D-0120 and Allopurinol in Healthy Adult Subjects

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: May 4, 2022
Registry last updated: Mar 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed